Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $8.9 million.

  • ImmunityBio's Share-based Compensation rose 1854.72% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 279.55%. This contributed to the annual value of $34.4 million for FY2024, which is 2996.36% down from last year.
  • Latest data reveals that ImmunityBio reported Share-based Compensation of $8.9 million as of Q3 2025, which was up 1854.72% from $9.6 million recorded in Q2 2025.
  • ImmunityBio's Share-based Compensation's 5-year high stood at $17.9 million during Q2 2021, with a 5-year trough of $7.5 million in Q3 2024.
  • For the 5-year period, ImmunityBio's Share-based Compensation averaged around $11.0 million, with its median value being $10.2 million (2022).
  • As far as peak fluctuations go, ImmunityBio's Share-based Compensation skyrocketed by 544751.55% in 2021, and later tumbled by 4816.94% in 2024.
  • ImmunityBio's Share-based Compensation (Quarter) stood at $10.2 million in 2021, then dropped by 8.15% to $9.4 million in 2022, then skyrocketed by 36.62% to $12.8 million in 2023, then dropped by 29.25% to $9.0 million in 2024, then decreased by 1.77% to $8.9 million in 2025.
  • Its Share-based Compensation stands at $8.9 million for Q3 2025, versus $9.6 million for Q2 2025 and $9.5 million for Q1 2025.